115 related articles for article (PubMed ID: 7849488)
1. Use of partially phosphorothioated "antisense" oligodeoxynucleotides for sequence-dependent modulation of hematopoiesis in culture.
Ehrlich G; Patinkin D; Ginzberg D; Zakut H; Eckstein F; Soreq H
Antisense Res Dev; 1994; 4(3):173-83. PubMed ID: 7849488
[TBL] [Abstract][Full Text] [Related]
2. Antisense inhibition of butyrylcholinesterase gene expression predicts adverse hematopoietic consequences to cholinesterase inhibitors.
Patinkin D; Lev-Lehman E; Zakut H; Eckstein F; Soreq H
Cell Mol Neurobiol; 1994 Oct; 14(5):459-73. PubMed ID: 7621507
[TBL] [Abstract][Full Text] [Related]
3. Cloning and antisense oligodeoxynucleotide inhibition of a human homolog of cdc2 required in hematopoiesis.
Lapidot-Lifson Y; Patinkin D; Prody CA; Ehrlich G; Seidman S; Ben-Aziz R; Benseler F; Eckstein F; Zakut H; Soreq H
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):579-83. PubMed ID: 1731328
[TBL] [Abstract][Full Text] [Related]
4. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
[TBL] [Abstract][Full Text] [Related]
5. Antisense inhibitory effect: a comparison between 3'-partial and full phosphorothioate antisense oligonucleotides.
Galderisi U; Di Bernardo G; Melone MA; Galano G; Cascino A; Giordano A; Cipollaro M
J Cell Biochem; 1999 Jul; 74(1):31-7. PubMed ID: 10381259
[TBL] [Abstract][Full Text] [Related]
6. Design of potent phosphorothioate antisense oligonucleotides directed to human interleukin 10 gene product and their evaluation of antisense activity in U937 cells.
Arima H; Takahashi M; Aramaki Y; Sakamoto T; Yuda K; Akiyama K; Goto T; Tsuchiya S
Pharm Res; 1999 Aug; 16(8):1163-71. PubMed ID: 10468015
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides.
Arima H; Sakamoto T; Aramaki Y; Ishidate K; Tsuchiya S
J Pharm Sci; 1997 Oct; 86(10):1079-84. PubMed ID: 9344161
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide down-regulation of E-cadherin in the yolk sac and cranial neural tube malformations.
Chen B; Hales BF
Biol Reprod; 1995 Nov; 53(5):1229-38. PubMed ID: 8527529
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Stein CA; Cheng YC
Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of interleukin-10 production in murine macrophage-like cells by phosphorothioate antisense oligonucleotides.
Arima H; Takahashi M; Aramaki Y; Sakamoto T; Tsuchiya S
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):319-27. PubMed ID: 9743469
[TBL] [Abstract][Full Text] [Related]
11. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao WY; Han FS; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
[TBL] [Abstract][Full Text] [Related]
12. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16.
Storey A; Oates D; Banks L; Crawford L; Crook T
Nucleic Acids Res; 1991 Aug; 19(15):4109-14. PubMed ID: 1651476
[TBL] [Abstract][Full Text] [Related]
13. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
14. Antisense inhibition of Na+/Ca2+ exchange in primary cultured arterial myocytes.
Slodzinski MK; Juhaszova M; Blaustein MP
Am J Physiol; 1995 Nov; 269(5 Pt 1):C1340-5. PubMed ID: 7491927
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
[TBL] [Abstract][Full Text] [Related]
16. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization.
Yaida Y; Nowak TS
Regul Pept; 1995 Oct; 59(2):193-9. PubMed ID: 8584754
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides.
Yao ZQ; Zhou YX; Wang AL; Bai XF; Yang WS
J Viral Hepat; 1995; 2(2):85-9. PubMed ID: 7493302
[TBL] [Abstract][Full Text] [Related]
18. Enhanced activity of antisense phosphorothioate oligos against leishmania amastigotes: augmented uptake of oligo, ribonuclease H activation, and efficient target intervention under altered growth conditions.
Mishra M; Porter-Kelley JM; Singh PK; Bennett JR; Chaudhuri G
Biochem Pharmacol; 2001 Sep; 62(5):569-80. PubMed ID: 11585054
[TBL] [Abstract][Full Text] [Related]
19. Antisense knockdown of PKC-alpha using LNA-oligos.
Hansen JB; Westergaard M; Thrue CA; Giwercman B; Oerum H
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1607-9. PubMed ID: 14565477
[TBL] [Abstract][Full Text] [Related]
20. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes.
Kanamaru T; Takagi T; Takakura Y; Hashida M
J Drug Target; 1998; 5(4):235-46. PubMed ID: 9713974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
